RESEARCH ARTICLE

Evidence of Active Pro-Fibrotic Response in Blood of Patients with Cirrhosis

Gloria Sanchez-Antolín, Carolina Almohalla-Alvarez, Pilar Bueno, Raquel Almansa, Verónica Iglesias, Lucia Rico, Alicia Ortega, Eva Muñoz-Conejero, Felix García-Pajares, Jesus F. Bermejo-Martin

1 Unidad de Hepatología, Unidad de Trasplante Hepático. Hospital Universitario Río Hortega, Valladolid, Spain, 2 Servicio de Análisis Clínicos, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 3 Investigación Médica en Infección e Inmunidad (IMI), Hospital Clínico Universitario de Valladolid-IECSCYL, Valladolid, Spain, 4 Escuela de Enfermería Universidad de Valladolid, Valladolid, Spain

☯ These authors contributed equally to this work.
* gloriasanchez_antolin@hotmail.com

Abstract

The role of systemic immunity in the pathogenesis of cirrhosis is not fully understood. Analysis of transcriptomic profiles in blood is an easy approach to obtain a wide picture of immune response at the systemic level. We studied gene expression profiles in blood from thirty cirrhotic patients and compared them against those of eight healthy volunteers. Most of our patients were male [n = 21, 70%] in their middle ages [57.4 ± 6.8 yr]. Alcohol abuse was the most frequent cause of cirrhosis (n = 22, 73%). Eleven patients had hepatocellular carcinoma (36.7%). Eight patients suffered from hepatitis C virus infection (26.7%). We found a signature constituted by 3402 genes which were differentially expressed in patients compared to controls (2802 over-expressed and 600 under-expressed). Evaluation of this signature evidenced the existence of an active pro-fibrotic transcriptomic program in the cirrhotic patients, involving the [extra-cellular matrix (ECM)-receptor interaction] & [TGF-beta signaling] pathways along with the [Cell adhesion molecules] pathway. This program coexists with alterations in pathways participating in [Glycine, serine and threonine metabolism], [Phenylalanine metabolism], [Tyrosine metabolism], [ABC transporters], [Purine metabolism], [Arachidonic acid metabolism]. In consequence, our results evidence the co-existence in blood of a genomic program mediating pro-fibrotic mechanisms and metabolic alterations in advanced cirrhosis. Monitoring expression levels of the genes involved in these programs could be of interest for predicting / monitoring cirrhosis evolution. These genes could constitute therapeutic targets in this disease.

Introduction

Intra-hepatic inflammation and immune response are known to play central roles in the pathogenesis of cirrhosis [1]. Both are direct causes of injury to hepatocytes and activation of hepatic stellate cells (HSCs), which ultimately leads to liver fibrosis[2]. In contrast, the participation of
the systemic immunological response in the pathogenesis of this disease has not been totally clarified. Analysis of transcriptomic profiles in peripheral blood is a widely accepted method to evaluate the complex immune networks that operate throughout the entire body. It has proven to be a valid approach for studying pathogenesis as well as to identifying potential biomarkers in a large variety of diseases[3]. While there are a number of previous works evaluating gene expression in hepatic tissue of cirrhotic patients or chronic liver diseases [4][5][6][7], there is very limited information on the transcriptomic profiles present in blood of these patients.

Our work unveils for the first time the presence of an active pro-fibrotic transcriptomic program in the blood of patients with liver cirrhosis, co-existing with alterations in the metabolome. Our findings evidence the important impact of cirrhosis on the immune response at the systemic level, providing also interesting clues on the potential roles of peripheral leukocytes in the pathogenesis of this disease.

Materials and Methods

Patients

We studied thirty cirrhotic patients of the Hepatology Unit of Hospital Univesitario Rio Hortega, Valladolid, Spain. We compared the study group with eight healthy volunteers who were in the same age range recruited from the staff of the Hospital, as control group. Approval of the study protocol for both the scientific and ethical aspects was obtained from the Scientific Committee for Clinical Research of “Hospital Universitario Río Hortega” (Comité de Ética en Investigación Clínica, CEIC-Área Oeste, Valladolid, Spain), conforming to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all participants before recruitment.

Sample collection

A sample of 2.5 mL of blood was collected from each patient using PaxGene venous blood vacuum collection tubes (Becton Dickinson, USA).

Microarray processing and data analysis

RNA extraction and processing for microarray analysis was performed as previously described by our group [8]. Data analysis was done using GeneSpring GX 12.0 software. The original data were cleaned and normalised in three steps: 1) local background was subtracted from the individual spot intensity; 2) log-transformed signal intensity values were globally normalised using the percentile shift algorithm, shifting to the 75th percentile of each sample, for per chip normalisation; and 3) baseline transformation of the data was performed using the median of all samples. Before statistical analyses, all microarrays were subjected to quality and filtering criteria. The quality of the microarray data was assessed on principal component analysis plots. Student’s t-tests (GeneSpring GX12.0) were used to identify genes that were differentially expressed between groups at a level of significance $p<0.05$, with Benjamini-Hochberg multiple testing corrections and fold changes $\geq 2$. DAVID (Database for Annotation, Visualization, and Integrated Discovery) & KEGG (Kyoto Encyclopedia of Genes and Genomes) were used to select, annotate and visualize genes by function and pathway[9][10]. Graphite Web software was used to represent signalling pathways present in the analysis[11]. The resulting microarray data sets were uploaded at the Array Express microarray data repository (E-MTAB-3338). Gene expression results from microarrays were validated using the Bio-Rad QX200 Droplet Digital PCR system as previously described[12]. Primers and probes were purchased to Life.
Technologies (Custom TaqMan assays with probes for problem genes labeled in FAM and housekeeping gene (GAPDH) labeled in VIC) (S1 Fig).

Results

Patients' clinical characteristics (Table 1)

Most of our patients were male in their middle ages. Alcohol abuse was the most frequent cause of cirrhosis in our cohort. There were eleven patients with hepatocellular carcinoma (HCC) (36.6%). Eight patients suffered from HCV infection (26.6%). The most frequent co-morbidities were diabetes mellitus and high blood pressure. The mean MELD (Model for End-Stage Liver Disease) score was 11.8, being the highest in the group of patients with no HCC. Patients with no HCC had lower albumin values and higher bilirubin levels. These patients showed in addition increased INR values. As expected, both groups of patients showed elevated levels of liver enzymes and also of C-reactive protein in serum. In turn, both had platelet counts in blood below normality.

Gene expression analysis

As said above, MELD score was lower in patients with HCC compared with that of patients with no HCC. Since this could influence gene expression profiles (GEP), we compared GEP in both groups of patients. Analysis revealed no differences between both groups regarding gene expression levels, and both groups were thus considered as a single one. Next, we compared the group of patients against healthy controls. This comparison revealed 3402 genes differentially expressed between patients with cirrhosis and controls (2802 up-regulated and 600 down-regulated) (S1 Table). DAVID/KEGG analysis revealed that these genes participate in three major groups of intracellular signaling pathways (S2 Table)(we highlight below those pathways identified by the analysis at the level \( p < 0.05 \)):

- **Signaling pathways involved in fibrogenesis**: [extra-cellular matrix (ECM)-receptor interaction] (Fig 1), [Transforming Growth Factor beta (TGF-beta) signaling pathway] (Fig 2).
- **Signaling pathways involved in cell adhesion**: [Cell adhesion molecules (CAMs)]
- **Signaling pathways involved in metabolism**: [Glycine, serine and threonine metabolism], [Phenylalanine metabolism], [Tyrosine metabolism], [ABC transporters], [Purine metabolism], [Arachidonic acid metabolism]

Discussion

Our study demonstrates that cirrhosis has an important impact on blood, evidencing the existence of an active transcriptomic program in circulating leukocytes, characterized by an enriched response in transcripts associated to fibrogenesis. This way, patients had a marked activation of the [ECM-receptor interaction] pathway. The extracellular matrix consists of a complex mixture of structural and functional macromolecules and serves an important role in tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function. Patients showed active production of three heparan-sulfate proteins pertaining to this pathway: Agrin (AGRN), heparan sulfate proteoglycan 2 (HSPG2) and syndecan 4 (SDC4). Heparan sulfate chains, the highly sulfated glycosaminoglycans attached to the protein core of heparan sulfate proteoglycans, are intricately involved in a variety of physiological processes such as morphogenesis, wound healing, regulation of cell differentiation and growth, and
establishment of cell–cell and cell–extracellular matrix contacts [13]. They accumulate in the matrix of the expanding scar tissue in chronic liver diseases [14]. In fact, agrin accumulates in the liver of patients with cirrhosis, and has been proposed to play a stimulatory role in neoangiogenic processes, and a supportive role in bile ductule proliferation [14]. SDC4 has been proposed to be a sensor of tension exerted on the extracellular matrix, which is an important event in wound contraction, tumor-stroma interactions, fibrosis and the regulation of motility [15]. In mice, SDC4 knockout protects against tubulointerstitial fibrosis in the kidney [16]. Expression of thrombospondin 1 (THBS1) and of three laminin genes (LAMC3, LAMA3/LAMA4, LAMB1) was activated also in our patients. It has been described that level of thrombospondin-1 (THBS-1) is higher in the serum of patients with hepatic fibrosis [17]. In turn, laminin is a major serum marker of liver fibrosis [18]. Patients had also increased expression of tenasin XB (TNXB). Tenascins constitute a family of matricellular proteins, primarily modulating interactions of cells with other matrix components and growth factors. Tenasin X has been shown to affect TGF-β activation and signalling, suggesting that these proteins might be important factors in fibrosis development [19]. Serum levels of Tenasin have been reported to reflect hepatic fibrogenesis and inflammation [20]. Patients with cirrhosis showed increased

### Table 1. Clinical characteristics of the patients.

|                      | TOTAL COHORT (n = 30) | HCC (n = 11) | NO HCC (n = 19) | p     | NRV       |
|----------------------|-----------------------|--------------|------------------|-------|-----------|
| **Age (mean ± SD)**  | 57.4 ± 6.8            | 58.3 ± 9.4   | 56.8 ± 7.1       | n.s.  | n.a       |
| **Male, n(%)**       | 21 (70)               | 8 (27)       | 13 (43)          | n.s.  | n.a       |
| **HCV infection**    | 3 (10)                | 1 (3.3)      | 2 (6.4)          | n.s.  | n.a       |
| **Alcoholism**       | 17 (58)               | 6 (20)       | 11 (38)          | n.s.  | n.a       |
| **HCV+Alcoholism**   | 5 (16)                | 3 (10)       | 2 (6)            | n.s.  | n.a       |
| **Other causes**     | 5 (16)                | 1 (3.3)      | 4 (12.8)         | n.s.  | n.a       |
| **Diabetes Mellitus II** | 8 (26)             | 3 (10)       | 5 (16)           | n.s.  | n.a       |
| **High blood pressure** | 11 (36)            | 6 (20)       | 5 (16)           | n.s.  | n.a       |
| **MELD score**       | 11.8±3.8              | 9.5 ± 2.7    | 13.2 ± 3.7       | 0.015 | n.a       |
| **Hemoglobin (g/dl)**| 11.5±2.4              | 12.6 ± 2.7   | 10.8 ± 1.9       | n.s.  | 13.2–16.8 |
| **Leukocytes (x10^3/μl)** | 5243.3±3328        | 4572.7 ± 2038| 5631.6 ± 3887.2  | n.s.  | 4–10.5    |
| **Neutrophil (%)**   | 64.2±16.4             | 63.3 ± 17.8  | 64.6 ± 15.8      | n.s.  | 41–72     |
| **Platelet (x10^3/μl)** | 91.5±48,9            | 89.2±35.0   | 94.6±56.1        | n.s.  | 150–350   |
| **ProthrombinTime (seconds)** | 78.6±20.2         | 88.6 ± 16.3  | 72.7 ± 20.4      | 0.030 | 60–140    |
| **INR**              | 1.2±0.3               | 1.1 ± 0.2    | 1.3 ± 0.4        | 0.007 | 0.8–1.2   |
| **Glucose (mg/dl)**  | 142.6±76.7            | 155 ± 87.0   | 134.8 ± 68.9     | n.s.  | 82–115    |
| **Albumin (g/dl)**   | 3.4±0.8               | 3.5 ± 0.6    | 2.9 ± 0.8        | 0.006 | 3.5–4.6   |
| **Bilirubin (mg/dl)**| 2.5±1.8               | 2.0 ± 1.3    | 2.9 ± 2.0        | 0.021 | 0.2–1.1   |
| **Cholesterol (mg/dl)** | 150.5±43.5          | 159.4 ± 32.9 | 143.6 ± 54.5     | n.s.  | <200      |
| **Triglycerides (mg/dl)** | 96.5±42.4          | 100.8±51.3  | 83.1±30.6        | n.s.  | <150      |
| **C Reactive Protein** | 30.8±81.6            | 12.9 ± 25.7  | 50.0±117.8       | n.s.  | 0–10      |
| **Uric Acid (mg/dl)**| 6.9±2.6              | 6.3±2.2      | 6.7 ± 3.2        | n.s.  | 2.6–6     |
| **AST (U/L)**        | 78.0±92.7            | 73 ± 45.4    | 84.0 ± 108.2     | n.s.  | 0–50      |
| **ALT (U/L)**        | 66±55.6              | 87 ± 75.9    | 58.0±34.9        | n.s.  | 1.0–55    |
| **GGT (U/L)**        | 160.1±203.9          | 173.8 ± 224.5| 136.4 ± 185.5    | n.s.  | 0–55      |
| **ALP (U/L)**        | 190.4±171.5          | 169.4 ± 91.3 | 209.5 ± 224.6    | n.s.  | 30–120    |

HCV: Hepatitis C Virus; HCC: hepatocellular carcinoma; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transpeptidase; ALP: alkaline phosphatase; INR: International Normalized Ratio coagulation index; MELD (Model for End-stage Liver Disease) score; NRV: normal reference values. N.a: not applicable.

doi:10.1371/journal.pone.0137128.t001
expression in blood of eight genes coding for collagen synthesis COL4A6, COL5A1, COL11A2, COL12A1, COL27A1, COL28A1, COL23A1, COL14A1. Although three other genes (COL4A4, COL6A2, COL5A3) were down-regulated in these patients, our results overall support the notion that white blood cells from patients with cirrhosis are predominately prone to produce collagen. Collagen genes are involved in activation of Hepatic Stellate Cells (HSCs), along with a number of genes also found to be up-regulated in our cohort of patients: colony stimulating factor 1 (macrophage) (CSF1), endothelin 1 (EDN1), fibroblast growth factor 1 (FGF1), insulin-like growth factor 2 (IGF2), lymphotoxin alpha (LTA), lymphocyte antigen 96 (LY96), myosin,
In the liver, activation of HSCs leads to collagen deposition and hepatic fibrogenesis [2][21]. IGF2 (somatomedin A) induces in addition proliferation of hepatocytes [22].

TGF-beta signaling pathway was also activated in the group of patients, with up-regulation of growth differentiation factor 7 (GDF7), inhibin, beta C(INHBC), ras homolog family member A(RHOA), latent transforming growth factor beta binding protein 1 (LTBP1), SMAD family member 5 (SMAD5), SMAD family member 9 (SMAD9), retinoblastoma-like 1 (p107) (RBL1), transcription factor Dp-1(TFDP1), THBS1, growth differentiation factor 5 (GDF5), inhibin, beta E(INHBE),chordin(CHRD) andring-box 1, E3 ubiquitin protein ligase(RBX1). Activation of this pathway is one of the most important stimuli for extracellular matrix synthesis at the systemic level, and also in the liver [23].

The top signaling pathway identified by KEGG was [Cell Adhesion molecules]. Genes of this pathway were up-regulated in their vast majority, supporting that leukocytes from cirrhotic patients are not only activated to mediate fibrogenesis, but also to leave circulation and interact with the extracellular matrix components[24].
We found also increased expression of caveolin-1 and caveolin-2 in blood in the group of patients with cirrhosis. Yokomori et al have recently reported caveolin-1 in liver sinusoidal endothelial cells to correlate with cirrhosis progression [25]. Caveolin-1 (CAV-1) is involved in hepatic sinusoidal angiogenesis and remodeling during progression to cirrhosis[25].

Severity of liver fibrosis in known to be associated to alterations in the metabolome[26][27][28]. According to this, our work demonstrates that cirrhosis induces a wide re-programming of transcriptomic signatures involved in metabolism, as evidenced by the observed alterations in the pathways participating in aminoacid, nucleotide and arachidonic acid metabolism.

Although there are limited works on gene expression profiles in blood from patients with liver diseases, some information is available. Shi M et al found a three-gene expression signature associated to early human hepatocellular carcinoma[29], constituted by the chemokine (C-X-C motif) receptor 2 (CXCR2), C–C chemokine receptor type 2 (CCR2) and the E1A-Binding Protein P400 (EP400). We failed to find this signature in our cohort of patients, neither comparing the total cohort with the controls, not when this comparison was performed considering just those patients with HCC and controls. Differences in the nature of the two works could explain this. The study of Shi et al was performed using RNA from peripheral blood mononuclear cells (PBMCs), while our study analyzed RNA from whole blood. In consequence, gene transcripts from neutrophils were considered in our work, but not in that from Shi et al.

In conclusion, our results evidence that cirrhosis is characterized by the presence of an active pro-fibrotic program at the transcriptomic level in blood. This program could be contributing to the pathogenesis of this disease and also to that of its extra-hepatic complications (i.e atherosclerosis, cardiovascular and brain disease). Blood is a sample much easier to access than liver biopsies. Monitoring the expression levels in blood of the genes participating in the signatures identified in this work could be of interest for predicting / monitoring cirrhosis evolution and their associated metabolic complications. In addition, further works should elucidate if the genes identified here could constitute therapeutic targets in this disease.

Supporting Information

S1 Fig. PCR validation of microarray data. Expression values obtained from the microarrays for COL27A1 and COL5A1 showed a significant positive correlation, confirmed by using digital PCR. FC: Fold Change.

S1 Table. List of genes differentially expressed genes between patients and controls. FC: fold change.

S2 Table. Database for Annotation, Visualization, and Integrated Discovery & Kyoto Encyclopedia of Genes and Genomes analysis showing the main intracellular signaling pathways differentially expressed between patients and controls.

Acknowledgments

We want to thank the nurse team of the Liver transplantation Unit for their dedication to our patients. We thank also to the Clinical analysis Service of our Hospital for performing the biochemistry and hematological works of this article.
Author Contributions
Conceived and designed the experiments: GSA JFBM RA. Performed the experiments: LR VI AO. Analyzed the data: GSA JFBM PB RA. Contributed reagents/materials/analysis tools: RA. Wrote the paper: RA PB GSA JFBM. Contributed to data collection and critical review of the manuscript: CAA EMC FGP.

References
1. Zhou W-C, Zhang Q-B, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol WJG. 2014; 20: 7312–7324. doi:10.3748/wjg.v20.i23.7312 PMID: 24966602
2. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013; 3: 1473–1492. doi:10.1002/cphy.c120035 PMID: 24265238
3. Chassaingel D, Pascual V, Banchereau J. Assessing the human immune system through blood transcriptomics. BMC Biol. 2010; 8: 84. doi:10.1186/1741-7007-8-84 PMID: 20619006
4. Aravinthan A, Shannon N, Heaney J, Hoare M, Marshall A, Alexander GJ. The senescent hepatocyte gene signature in chronic liver disease. Exp Gerontol. 2014; 60: 37–45. doi: 10.1016/j.exger.2014.09.011 PMID: 25240687
5. Ahmad W, Ijaz B, Hassan S. Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med. 2012; 10: 41. doi:10.1186/1479-5876-10-41 PMID: 22397681
6. Estep JM, O’Reilly L, Grant G, Piper J, Jonsson J, Afendy A, et al. Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation. Dig Dis Sci. 2010; 55: 496–504. doi:10.1007/s10620-009-0919-9 PMID: 19680808
7. Utsunomiya T, Okamoto M, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, et al. A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol WJG. 2007; 13: 383–390. PMID: 17230606
8. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37: 1–13. doi:10.1093/nar/gkn923 PMID: 19033363
9. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44–57. doi: 10.1038/nprot.2008.211 PMID: 19131956
10. Utsunomiya T, Okamoto M, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, et al. A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol WJG. 2007; 13: 383–390. PMID: 17230606
11. Almansa R, Heredia-Rodríguez M, Gomez-Sanchez E, Andaluz-Ojeda D, Iglesias V, Rico L, et al. Transcriptomic correlates of organ failure extent in sepsis. J Infect. 2015; 70: 445–456. doi:10.1016/j.jinf.2014.12.010 PMID: 25557485
12. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007; 446: 1030–1037. doi:10.1038/nature05817 PMID: 17460664
13. Tátrai P, Dudás J, Batmunkh E, Máté M, Zalatnai A, Schaff Z, et al. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest J Tech Methods Pathol. 2006; 86: 1149–1160. doi:10.1038/labinvest.3700475
14. Okina E, Manon-Jensen T, Whiteford JR, Couchman JR. Syndecan proteoglycan contributions to cytoskeletal organization and contractility. Scand J Med Sci Sports. 2009; 19: 479–489. doi:10.1111/j.1600-0838.2009.00941.x PMID: 19358537
15. Scarpellini A, Huang L, Burhan I, Schroeder N, Funck M, Johnson TS, et al. Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis. J Am Soc Nephrol JASN. 2014; 25: 1013–1027. doi:10.1681/ASN.2013050563 PMID: 24357671
16. Zhang B, Wang Z, Deng B, Wu X, Liu J, Feng X. Identification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics. Proteome Sci. 2013; 11: 30. doi:10.1186/1477-5966-11-30 PMID: 23845056
17. Zhu C, Qi X, Li H, Peng Y, Dai J, Chen J, et al. Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective cross-sectional study. Int J Clin Exp Med. 2015; 8: 5989–5998. PMID: 26131195
19. Kasprzycka M, Hammarström C, Haraldsen G. Tenascins in fibrotic disorders—from bench to bedside. Cell Adhes Migr. 2015; 9: 83–89. doi:10.4161/19336918.2014.994901

20. Lebensztejn D-M, Sobaniec-Lotowska M-E, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol WJG. 2006; 12: 3338–3343. PMID: 16733849

21. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011; 25: 195–206. doi:10.1016/j.bpg.2011.02.005 PMID: 21497738

22. Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, et al. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer. 2014; 9: 27. doi:10.1186/1750-9378-9-27 PMID: 25225571

23. Kovalesky I, Nagy P, Szende B, Lapis K, Szalay F, Jeney A, et al. Experimental and human liver fibrogenesis. Scand J Gastroenterol Suppl. 1998; 228: 51–55. PMID: 9867113

24. Yue B. Biology of the extracellular matrix: an overview. J Glaucoma. 2014; 23: S20–23. doi:10.1097/IJG.0000000000000108 PMID: 25275899

25. Yokomori H, Ando W, Yoshimura K, Yamazaki H, Takahashi Y, Oda M. Increases in endothelial caveolin-1 and cavins correlate with cirrhosis progression. Micron Oxf Engl. 1993. 2015; 76: 52–61. doi:10.1016/j.micron.2015.03.009

26. Sands CJ, Guha IN, Kyriakides M, Wright M, Beckonert O, Holmes E, et al. Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis. Am J Gastroenterol. 2015; 110: 159–169. doi:10.1038/aig.2014.370 PMID: 25533003

27. Tessari P, Vettore M, Millioni R, Puricelli L, Orlando R. Effect of liver cirrhosis on phenylalanine and tyrosine metabolism. Curr Opin Clin Nutr Metab Care. 2010; 13: 81–86. doi:10.1097/MCO.0b013e32833383af PMID: 19898234

28. Sacrdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M, Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat. 2015; 10.1016/j.prostaglandins.2015.05.008

29. Shi M, Chen M-S, Sekar K, Tan C-K, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer Oxf Engl. 1990. 2014; 50: 928–936. doi:10.1016/j.ejca.2013.11.026